Respiratory syncytial virus infection in high-risk infants - An update on palivizumab prophylaxis

Open Microbiology Journal

Volumn 8, Issue 1, 2014, Pages 71-77

  Resch, Bernhard ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Palivizumab; Prophylaxis; Respiratory syncytial virus; Respiratory tract infection

Indexed keywords

MOTAVIZUMAB; PALIVIZUMAB;

ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONGENITAL DIAPHRAGM HERNIA; CONGENITAL HEART DISEASE; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DOWN SYNDROME; GESTATIONAL AGE; HUMAN; IMMUNE DEFICIENCY; LUNG DYSPLASIA; LUNG VOLUME; META ANALYSIS (TOPIC); NEOPLASM; PNEUMOVIRUS INFECTION; PRACTICE GUIDELINE; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY SYNCYTIAL VIRUS INFECTION; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); CHILDHOOD CANCER; DRUG EFFICACY; HIGH RISK INFANT; NEUROMUSCULAR DISEASE;

RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 84919451804     PISSN: None     EISSN: 18742858     Source Type: Journal    
DOI: 10.2174/1874285801408010071     Document Type: Article

References (41)

1. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375: 1545-55.
2. Garcia CG, Bhore R, Soriano-Fallas A, et al. Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis. Pediatrics 2010; 126: e1453-60.
3. Brand HK, de Groot R, Galama JM, et al. Infection with multiple viruses is not associated with increased disease severity in children with bronchiolitis. Pediatr Pulmonol 2012; 47: 393-400.
4. Resch B. Palivizumab for the prophylaxis of respiratory syncytial virus infection. Paed Health 2008; 2: 265-78.
5. Resch B. Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-risk infants. Expert Rev Pharmacoecon Outcomes Res 2008; 8: 529-38.
6. Resch B, Resch E, Müller W. Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus infection? The case in favour. Paediatr Respir Rev 2013; 14: 130-6.
7. Paes B, Mitchell I, Li A, Harimoto T, Lanctôt KL. Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries. Clin Dev Immunol 2013; 2013: 917068.
8. Papenburg J, Hamelin MÈ, Ouhoummane N, et al. Comparison of risk factors for human metapneumovirus and respiratory syncytial virus disease severity in young children. J Infect Dis 2012; 206: 178-89.
9. Paes B, Mitchell I, Li A, Lanctôt KL. CARESS Investigators. A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS). Eur J Clin Microbiol Infect Dis 2012; 31: 2703-11.
10. Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements-Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 124:1694-701.
11. Makari D, Checchia PA, Devincenzo J. Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus. Hum Vaccin Immunother 2013; 10. [Epub ahead of print].
12. Blanken MO, Koffijberg H, Nibbelke EE, Rovers MM, Bont L. Dutch RSV Neonatal Network. Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study. PLoS One 2013; 8: e59161.
13. Doering G, Gusenleitner W, Belohradsky BH, Burdach S, Resch B, Liese JG. The risk of respiratory syncytial virus-related hospitalizations in preterm infants of 29 to 35 weeks' gestational age. Pediatr Infect Dis J 2006; 25: 1188-90.
14. Simões EA, Carbonell-Estrany X, Fullarton JR, et al. European RSV Risk Factor Study Group. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res 2008; 9: 78.
15. Paes B, Steele S, Janes M, Pinelli J. Risk-scoring tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada. Curr Med Res Opin 2009; 25: 1585-91.
16. Krilov LR, Palazzi DL, Fernandes AW, Klein RW, Mahadevia PJ. Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States. Value Health 2010; 13: 77-86.
17. DiFranza JR, Masaquel A, Barrett AM, Colosia AD, Mahadevia PJ. Systematic literature review assessing tobacco smoke exposure as a risk factor for serious respiratory syncytial virus disease among infants and young children. BMC Pediatr 2012; 12: 81.
18. Régnier SA, Huels J. Association between respiratory syncytial virus hospitalizations in infants and respiratory sequelae: systematic review and meta-analysis. Pediatr Infect Dis J 2013; 32: 820-6.
19. Blanken MO, Rovers MM, Molenaar JM, et al. Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013; 368: 1791-9.
20. Resch B, Michel-Behnke I. Respiratory syncytial virus infections in infants and children with congenital heart disease: update on the evidence of prevention with palivizumab. Curr Opin Cardiol 2013; 28: 85-91.
21. Chemaly RF, Ghantoji SS, Shah DP, et al. Respiratory syncytial virus infections in children with cancer. J Pediatr Hematol Oncol 2013; Dec 10. [Epub ahead of print].
22. Robinson KA, Odelola OA, Saldanha IJ, McKoy NA. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev 2013 Jun 5; 6:CD007743.
23. Sánchez-Solis M, Gartner S, Bosch-Gimenez V, Garcia-Marcos L. Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients? A meta-analysis. Allergol Immunopathol (Madr) 2013; Nov 11. [Epub ahead of print].
24. Bloemers BL, van Furth AM, Weijerman ME, et al. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis--a prospective birth-cohort study. Pediatrics 2007; 120: e1076-81.
25. Bloemers BL, Broers CJ, Bont L, Weijerman ME, Gemke RJ, van Furth AM. Increased risk of respiratory tract infections in children with Down syndrome: the consequence of an altered immune system. Microbes Infect 2010; 12: 799-808.
26. Paes B, Mitchell I, Yi H, Li A, Lanctôt KL. CARESS Investigators. Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab. Pediatr Infect Dis J 2014; 33: e29-33.
27. Simon A, Prusseit J, Müller A. Respiratory syncytial virus infection in children with neuromuscular impairment. Open Microbiol J 2011; 5: 155-8.
28. Resch B, Manzoni P, Lanari M. Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes. Paediatr Respir Rev 2009; 10: 148-53.
29. Fauroux B. Special populations. Paediatr Respir Rev 2009; 10 (Suppl 1): 21-2.
30. Asner S, Stephens D, Pedulla P, Richardson SE, Robinson J, Allen U. Risk factors and outcomes for respiratory syncytial virus-related infections in immunocompromised children. Pediatr Infect Dis J 2013; 32: 1073-6.
31. Manzoni P, Paes B, Resch B, Carbonell-Estrany X, Bont L. High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention. Early Hum Dev 2012; 88 (Suppl 2): S34-41.
32. Gaboli M, de la Cruz OA, de Agüero MI, Moreno-Galdó A, Pérez GP, de Querol MS. Use of palivizumab in infants and young children with severe respiratory disease: a delphi study. Pediatr Pulmonol 2013 Jun 18. doi: 10.1002/ppul.22826 [Epub ahead of print].
33. Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, BacicVrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev 2013; 4: CD006602.
34. Wang D, Bayliss S, Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Health Technol Assess. 2011; 15: iii-iv, 1-124.
35. Mahadevia PJ, Masaquel AS, Polak MJ, Weiner LB. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective. J Med Econ 2012; 15: 987-96.
36. Weiner LB, Masaquel AS, Polak MJ, Mahadevia PJ. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States. J Med Econ 2012; 15: 997-1018.
37. Resch B, Sommer C, Nuijten MJ, et al. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria. Pediatr Infect Dis J 2012; 31: e1-8.
38. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531-7.
39. Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M. Palivizumab Outcomes Registry Group. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol 2008; 28: 511-7.
40. Feltes TF, Cabalka AK, Meissner HC, et al. Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143: 532-40.
41. Cohen SA, Zanni R, Cohen A, Harrington M, VanVeldhuisen P, Boron ML. Palivizumab Outcomes Registry Group. Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 Palivizumab Outcomes Registry. Pediatr Cardiol 2008; 29: 382-7.